Objective To investigate the efficacy and toxic and adverse effects of high- dose hypofractionated radiotherapy in elderly patients with stage Ⅳ pancreatic cancer. Methods The clinical data of the patients with pancreatic cancer and distant metastasis who were admitted to our hospital from September 2011 to May 2015 were collected,and all the patients underwent high- dose hypofractionated helical tomotherapy. The data on efficacy and toxic and adverse effects were obtained through follow- up,and the evaluation of adverse effects was performed according to National Cancer Institute- Common Terminology Criteria for Adverse Events version 4. 02. The Kaplan- Meier method was used for survival analysis. Results A total of 33 patients older than 65 years received the high- dose hypofractionated radiotherapy.Of all the patients,30 received follow- up visits,and the follow- up rate was 91. 0%. The median survival time was 9 months,the 1- year overall survival rate was 24. 0%,and the rate of pain relief was 80. 0%( 20 /25). The treatment outcome of pancreatic lesions could be evaluated in 17 patients,among whom 4( 23. 5%) achieved partial remission,12( 70. 6%) achieved stable disease,and 1( 5. 9%) experienced progression. As for toxic and adverse effects,the incidence rate of grade 3 hematologic toxicity was 6. 7%( 2 /30),and no patients experienced grade > 2 upper gastrointestinal reactions. Conclusion In elderly patients with stage IV pancreatic cancer,high- dose hypofractionated radiotherapy has tolerable toxic and adverse effects and can relieve cancer pain and prolong survival time.
[1]CANNISTRA M,RUGGIERO M,ZULLO A,et al.Metastases of pancreatic adenocarcinoma:A systematic review of literature and a new functional concept[J].Int J Surg,2015,21(Suppl 1):s15-s21.
|
[2]CONROY T,DESSEIGNE F,YCHOU M,et al.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J].N Engl J Med,2011,364(19):1817-1825.
|
[3]GOLDSTEIN D,EL-MARAGHI RH,HAMMEL P,et al.nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer:long-term survival from a phaseⅢtrial[J].J Natl Cancer Inst,2015,107(2).Pii:dju413.
|
[4]REN G,XIA T,WANG Y.IMRT with capecitabine in advanced pancreatic cancer.In regard to Passoni et al[J].Int J Radiat Oncol Biol Phys,2014,89(2):431.
|
[5]XIA T,CHANG D,WANG Y,et al.Dose escalation to target volumes of helical tomotherapy for pancreatic cancer in the phase I-II clinical trial[J].Int J Radiat Oncol Biol Phys,2013,87(Suppl):s303.
|
[6]MAHADEVAN A,MIKSAD R,GOLDSTEIN M,et al.Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer[J].Int J Radiat Oncol Biol Phys,2011,81(4):e615-e622.
|
[7]WANG J,XIA T,WANG Y,et al.Long-term results of gamma ray-based stereotactic body radiotherapy in treatment of medically unfit or inoperable non-metastatic pancreatic adenocarcinoma[J].Int J Radiat Oncol Biol Phys,2012,84(Suppl):s815-s816.
|
[8]REN G,WANG J,XIA TY.Interpretation of radiotherapy document in Chinese expert consensuson comprehensive diagnosis and treatment of pancreatic cancer(2014 Edition)[J].J Clin Hepatol,2014,30(12):1249-1252.(in Chinese)任刚,王竞,夏廷毅.《胰腺癌综合诊治中国专家共识(2014年版)》放疗部分解读[J].临床肝胆病杂志,2014,30(12):1249-1252.
|
[9]LIN JC,JEN YM,LI MH,et al.Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer[J].Eur J Gasteroenterol Hepatol,2015,27(3):259-264.
|
[10]YECHIELI RL,ROBBINS JR,MAHAN M,et al.Stereotactic body radiotherapy for elderly patients with medically inoperable pancreatic cancer[J].Am J Clin Oncol,2014.[Epub ahead of print]
|
[11]KIM CH,LING DC,WEGNER RE,et al.Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients[J].Radiat Oncol,2013,8:240.
|
[12]PAN Y,LIU LM,CHEN Z,et al.Prognostic analysis of 190 elgerly patients with pancreatic cancer treated by integrated traditional chinese and western medicine therapy[J].J Clin Hepatol,2014,30(4):330-334.(in Chinese)潘岩,刘鲁明,陈震,等.中西医结合治疗190例老年胰腺癌的预后分析[J].临床肝胆病杂志,2014,30(4):330-334.
|